Combined archive search across FBI Vault, SPLC, PHMPT, ACIP, NIH grants, the Federal Writers' Project, and other collections we've ingested.
Matthew J. Flick · UNIV OF NORTH CAROLINA CHAPEL HILL · 2024 · $531,940 — SUMMARY Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2; CoV2) is the first highly pathogenic and highly transmissible human coronavirus that is the causative agent for the worldwide COVID-19 pandemic. As of November 2020, 50 million cases of CoV2 infection worldwide and 1.25 million dea…
GR Scott Budinger · NORTHWESTERN UNIVERSITY AT CHICAGO · 2024 · $725,783 — PROJECT SUMMARY This application directly stems from our recent publication in Nature in which we analyzed bronchoalveolar lavage (BAL) fluid from 88 patients with critical SARS-CoV-2 pneumonia using a combination of flow cytometry, bulk transcriptomic profiling of flow sorted alveolar macrophages a…
KENNETH E BERNSTEIN · CEDARS-SINAI MEDICAL CENTER · 2024 · $560,426 — A long sought goal of medical research is to identify ways to increase the effectiveness of the immune response. Here, we present a means of increasing myeloid cell function by increasing cell expression of angiotensin converting enzyme (ACE). We show that 1) under natural circumstances in both huma…
ALEXEY VLAD ONUFRIEV · VIRGINIA POLYTECHNIC INST AND ST UNIV · 2024 · $297,987 — Project Summary. This proposal responds to PAR-19-253 “Focused Technology Research and Development”. Our main goal is to develop a novel class of implicit solvation models, as accurate, and even more accurate, than standard explicit solvent models, but much faster. The high accuracy, fast implicit s…
Stijn Piet Johan De Langhe · MAYO CLINIC ROCHESTER · 2024 · $934,920 — Idiopathic pulmonary fibrosis (IPF) is a common form of interstitial lung disease (ILD), resulting in alveolar remodeling and progressive loss of pulmonary function, respiratory failure, and death often within 5 years of diagnosis. Genetic and experimental evidence support the concept that chronic a…
Andrei A Vakhtin · LOVELACE BIOMEDICAL RESEARCH INSTITUTE · 2024 · $709,373 — ABSTRACT: Approximately one third of non-hospitalized coronavirus disease of 2019 (COVID-19) patients report chronic symptoms after recovering from the acute stage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Some of the most persistent and common complaints of this pos…
Lisa Anne Vrooman · OREGON HEALTH & SCIENCE UNIVERSITY · 2024 · $493,409 — PROJECT SUMMARY There is evidence from human and animal studies that support that imbalance in the renin-angiotensin system (RAS), specifically reduced ACE2 protein levels and/or activity, leads to adverse maternal and fetal outcomes. Mouse dams and concepti with loss-of-function alleles of ACE2 exh…
Chien-Ting Wu · UT SOUTHWESTERN MEDICAL CENTER · 2024 · $499,989 — Project Summary Human respiratory tissues have a unique cellular architecture and a mucus-based clearance system that, together, constitute an impressive barrier to viruses that use the airway epithelium as their portal of entry. The mucus-based clearance system acts as a physical, innate defense me…
Shelli Farhadian · YALE UNIVERSITY · 2024 · $417,822 — Project Summary The COVID-19 pandemic has rampantly affected the population of the world and created lasting effects on the economy, health and psyche of the global community. Although it shares similarities with SARS-CoV-1, the full extent of the pathophysiology caused by SARS-CoV-2 is unclear. In …
Todd B Reynolds · UNIVERSITY OF TENNESSEE KNOXVILLE · 2024 · $518,119 — Candida albicans and related Candida spp. are responsible for ~400,000 invasive infections/year, which have an ~50% mortality rate. A crucial virulence trait of C. albicans, and other fungi, is the ability to diminish their detection by their hosts. The cell wall carbohydrate ß(1,3)-glucan is an imp…
Ralph S Baric · WASHINGTON UNIVERSITY · 2024 · $1,193,360 — Project Summary Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense single-stranded RNA virus that was first isolated in Wuhan China in December, 2019. SARS-CoV-2 is the cause of coronavirus disease 2019 (COVID-19), which is now a pandemic and has caused more than 1.3 mi…
Megan A O'Connor · UNIVERSITY OF WASHINGTON · 2024 · $785,351 — PROJECT SUMMARY/ABSTRACT COVID-19 vaccination reduces the risk of SARS-CoV-2 infection and severe disease, but almost half of hospitalized breakthrough cases are in immunocompromised individuals. HIV infection is an independent risk factor for severe COVID-19, hospitalization, and mortality. Immunoc…
Han Peng · NORTHWESTERN UNIVERSITY AT CHICAGO · 2024 · $481,939 — PROJECT SUMMARY/ABSTRACT The long-term goal of this project is to understand the functions of selective autophagy in corneal inflammation as well as corneal/limbal epithelial differentiation. Selective autophagy is a specialized form of autophagy and can control signaling pathways in cells by specif…
Daniel Barber · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $397,520 — SARS-CoV-2 infection has a spectrum of clinical disease outcomes, ranging from asymptomatic to fatal. The severity of COVID-19 is largely determined by the degree of virus-induced damage and immune-mediated pathology. However, the factors that prevent or promote pulmonary inflammation during SARS-Co…
Natalie Shaw · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · 2024 · $148,560 — We confirmed increased ACE2 mRNA and protein expression and functional activity (via a fluorometric assay) in SMCHD1 KO human placode cells. We are now conducting molecular and genomic studies, including RNA-seq, Hi-C, and SMCHD1 ChIP-seq, studies to investigate the precise mechanism underlying epig…
Peter Skene · SEATTLE CHILDREN'S HOSPITAL · 2024 · $871,800 — Abstract The immune system is composed of many heterogeneous cell types that respond in a synergistic manner to mount both immediate and long-lived immunity against pathogens. The complexity of the immune system necessitates an integrated view of multiple biological modalities to understand differen…
Blake Marie Hauser · HARVARD MEDICAL SCHOOL · 2023 · $52,694 — Project Summary/Abstract Since the emergence of the novel severe acute respiratory syndrome virus 2 (SARS-CoV-2) coronavirus, the need for better frameworks to rapidly develop vaccines in response to emerging viral threats, including other coronaviruses of potential pandemic concern, is clear. One a…
Stijn Piet Johan De Langhe · MAYO CLINIC ROCHESTER · 2023 · $954,000 — Idiopathic pulmonary fibrosis (IPF) is a common form of interstitial lung disease (ILD), resulting in alveolar remodeling and progressive loss of pulmonary function, respiratory failure, and death often within 5 years of diagnosis. Genetic and experimental evidence support the concept that chronic a…
Mingtao Zhao · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · 2023 · $195,000 — Down syndrome (DS) is the most common genetic disorder occurring in about 1 in 800 live births, and is characterized by a distinctive facial appearance, intellectual disability, and developmental delays. Gene dosage imbalance in DS patients, primarily caused by an extra copy of chromosome 21 (trisom…
ELLIOTT D CROUSER · OHIO STATE UNIVERSITY · 2023 · $543,218 — The SARS CoV-2 pandemic has resulted in >550,000 deaths in the USA alone. Therapeutic options for critically ill patients with COVID-19 are limited. Prior studies showed that development of severe hypoxemia and lung inflammation in influenza A virus-infected mice is associated with inhibition of de …